• Home
  • Study Details
Coming Soon

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Early-Stage Breast Cancer

The purpose of this study is to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen. This study will help the study doctors find out if this different approach is the same as the usual approach. To decide if it is better, the study doctors will be looking to see if low-dose tamoxifen has the same chance of preventing breast cancer from returning compared to the usual hormonal therapy medications with less side effects

Age & Gender

  • 18 years ~ 99 years
  • Female

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Lisa Carey
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)
Women's Health

IRB Number

25-0585

ClinicalTrials.gov

NCT06671912

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research